Potential mortality benefit from secondary prophylaxis following CMV treatment completion may be due to confounding by transplant organ type

Transpl Infect Dis. 2019 Apr;21(2):e13051. doi: 10.1111/tid.13051. Epub 2019 Feb 6.

Authors

Bradley J Gardiner^{1

2}, Jennifer K Chow¹, David R Snydman^{1

3}

Affiliations

¹ Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts.
² Department of Infectious Disease, Alfred Health and Monash University, Melbourne, Australia.
³ Tufts Clinical and Translational Science Institute, Tufts University, Boston, Massachusetts.

PMID: 30667578
DOI: 10.1111/tid.13051

No abstract available

Publication types

Letter
Comment

MeSH terms

Cytomegalovirus
Cytomegalovirus Infections*
Ganciclovir
Humans
Organ Transplantation*

Substances

Ganciclovir